Ordiss, 32mg pills 30pcs

Composition

1 tablet contains:

Active ingredient:

candesartan cilexetil 32.0 mg

Pharmacological action

Angiotensin II is the main hormone of the renin-aigiotensin-aldosterone system (RAAS), which plays an important role in the pathogenesis of arterial hypertension, heart failure and other cardiovascular diseases.

The main physiological effects of angiotensin II are vasoconstriction, stimulation of aldosterone production, regulation of the water-electrolyte state, and stimulation of cell growth. The effects are mediated by the interaction of angiotensin II with angiotensin type 1 receptors (AT1 receptors).

 Candesartan is a selective antagonist of angiotensin II AT1 receptors, does not inhibit the angiotensin – converting enzyme (ACE) that converts angiotensin I to angiotensin II, which destroys bradykinin, does not lead to the accumulation of bradykinin or substance P. As a result of blocking AT1 receptors of angiotensin II, there is a dose-dependent increase in the content of renin, angiotensin I, angiotensin II and a decrease in the concentration of aldosterone in the blood plasma.

When comparing candesartan with ACE inhibitors, the development of cough was less common in patients receiving candesartan.

Candesartan does not bind to the receptors of other hormones and does not block ion channels involved in regulating the functions of the cardiovascular system.

Indications

Arterial hypertension.

Contraindications

Severe hepatic insufficiency and / or cholestasis, pregnancy, lactation (breastfeeding), hypersensitivity to candesartan.

Side effects

From the central nervous system: dizziness.

Respiratory system disorders: cough, flu-like symptoms, rhinitis, pharyngitis, increased incidence of respiratory infections.

From the digestive system: abdominal pain.

From the cardiovascular system: peripheral edema.

Other services: possible back pain.

Interaction

When used concomitantly with potassium preparations, potassium-sparing diuretics, dietary supplements containing potassium, or potassium salt substitutes, hyperkalemia may develop.

Medications that affect RAAS may increase blood urea and creatinine concentrations in patients with bilateral renal artery or single kidney artery stenosis. Concomitant use of diuretics and other antihypertensive agents increases the risk of hypotension.

Candesartan increases the concentration of lithium in the blood serum and increases the risk of toxic reactions.

How to take, course of use and dosage

Take orally 1 time/day. The initial dose is 4 mg, the maintenance dose is 8 mg, and the maximum dose is 16 mg.

For patients with impaired liver and/or kidney function, the initial dose is 2 mg.

Overdose

Symptoms:  analysis of the pharmacological properties of the drug suggests that the main manifestation of overdose may be a clinically pronounced decrease in blood pressure, dizziness. Individual cases of overdose of the drug (up to 672 mg of candesartan) were described, which resulted in recovery of patients without serious consequences.

Treatment:  with the development of a clinically pronounced decrease in blood pressure, it is necessary to conduct symptomatic treatment and monitor the patient’s condition. Place the patient on his back and lift his legs. If necessary, the BCC should be increased, for example, by intravenous use of 0.9% sodium chloride solution. If necessary, sympathomimetic agents can be used. Elimination of candesartan by hemodialysis is ineffective.

Special instructions

It is not recommended for use in patients with severe renal insufficiency (creatinine clearance less than 15 ml / min), with primary hyperaldosteronism.

Before starting treatment with candesartan, correction of water-electrolyte balance disorders should be performed.

When used in patients with renal insufficiency, the level of potassium and creatinine in the blood plasma should be periodically monitored.

Use with caution in patients with hemodynamic disorders caused by aortic or mitral stenosis, with obstructive hypertrophic cardiomyopathy.

It should be borne in mind that in patients with ischemic cardiopathy, ischemic cerebrovascular diseases, severe arterial hypotension can lead to the development of myocardial infarction or stroke.

Influence on the ability to drive motor vehicles and manage mechanisms

If it is necessary to use candesartan in patients engaged in potentially dangerous activities (including driving vehicles), it should be borne in mind that candesartan can cause dizziness and weakness.

Form of production

Tablets

Active ingredient

Candesartan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Hypertension, Heart Failure